Institut De Recherches Internationales Servier

This early-stage study tested a new oral drug, AG-881, in adults with advanced solid tumors, including a type of brain tumor called glioma, that have specific IDH gene mutations. The main goals were to find a safe dose and see how the body processes the drug. Researchers enrolled…

This first-in-human study tested a new oral drug, AG-120, designed to target a specific genetic flaw (IDH1 mutation) found in several advanced solid tumors, including certain brain, bile duct, and bone cancers. The main goals were to find the safest and most effective dose and to…

This early-stage study tested two drugs, AG-120 and AG-881, in adults with a recurring, slow-growing brain tumor that has a specific genetic change (IDH1 mutation). The main goal was to see if taking one of these drugs before planned surgery could lower levels of a harmful chemic…